查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1983209

高活性藥物成分（HPAPI）和細胞毒性藥物市場：按藥物來源、製造地、藥物類型、藥物分子類型、應用和地區分類

HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Origin, By Manufacturing Location, By Drug Type, By Type of Pharmacological Molecule, By Application, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2026 年，高活性藥物成分 (HPAPI) 和細胞毒性藥物市場規模將達到 377.8 億美元，到 2033 年將達到 648.1 億美元。預計 2026 年至 2033 年的複合年成長率將達到 8%。

分析範圍 分析詳情
基準年 2025 市場規模（2026 年） 377.8億美元
效能數據 2020-2024 預測期 2026-2033
預測期（2026-2033 年）複合年成長率 8.00% 預計金額（2033 年） 648.1億美元

高活性療效原料藥（HPAPI）在藥物研發管線中，包括癌症治療領域，正佔越來越重要的佔有率。高活性藥物成分的大規模生產需要豐富的HPAPI計劃經驗，以及可靠的審計和供應穩定性記錄。

細胞毒性藥物是指透過抑制細胞分裂來破壞癌細胞和腫瘤的藥物。這些藥物被廣泛用作抗癌藥物，以增強手術和放射線治療的療效、抑制轉移並緩解癌症症狀。

市場動態

市場參與企業正積極進行非內內部成長活動，例如收購，以拓展產品系列，預計將推動全球高活性藥物成分（HPAPI）和細胞毒性藥物市場在預測期內的成長。例如，2019年1月，生命科學公司Frama Group收購了梯瓦製藥位於美國馬爾文的化學合成中心，該中心佔地4萬平方英尺，符合cGMP標準。該實驗室和製造地包括一座具備氫化能力的cGMP先導工廠、濕式研磨設備、五個標準cGMP千噸實驗室以及一個cGMP高活性藥物成分（HPAPI）千噸實驗室。

主要企業正集中精力為其生產設施獲得監管部門的批准，預計這將推動全球高活性藥物成分（HPAPI）和細胞毒性藥物市場在預測期內的成長。例如，2019年12月，Cerbios-Pharma SA宣布其符合cGMP標準的生物偶聯生產線已獲得瑞士藥品監管機構Swissmedic的批准，可用於抗體藥物複合體（ADC）的商業化生產。

此外，2019 年 12 月，Piramal Enterprises Ltd. 的一個業務部門 Piramal Pharma Solutions 擴建了其位於密西根州 Riverview 的生產設施，投資約 3,200 萬美元，用於開發和生產高活性和低活性藥物原料藥(API)。

本報告的主要特點

  • 本報告指出了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
  • 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
  • 本文檔根據以下參數介紹了全球高活性藥物成分 (HPAPI) 和細胞毒性藥物市場中主要企業的概況：公司概況、產品系列、主要亮點、財務績效和策略。
  • 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
  • 《全球高活性藥物成分和細胞毒性藥物市場》報告面向該行業的眾多相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
  • 相關人員可以透過分析全球高活性藥物成分和細胞毒性藥物市場中使用的各種策略矩陣來促進決策。

目錄

第1章：分析目標與假設

  • 分析目的
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機遇
  • 影響分析
  • 法規環境
  • PEST分析
  • 近期產品發布及核准
  • 流行病學
  • 併購

第4章 全球高活性藥物成分與細胞毒性藥物市場：依藥物來源分類（2026-2033 年）

  • 化學衍生的高活性藥物成分
  • 生物來源的HPAPI

第5章 全球高活性藥物成分與細胞毒性藥物市場：依製造地分類（2026-2033 年）

  • 內部生產
  • 外包

第6章 全球高活性藥物成分與細胞毒性藥物市場：依藥物類型分類（2026-2033 年）

  • 新的惠普 API
  • 非專利HPAPI

第7章 全球高活性藥物成分與細胞毒性藥物市場：依藥物分子類型分類（2026-2033 年）

  • 低分子化合物
  • 生物製藥

第8章 全球高活性藥物成分和細胞毒性藥物市場：按應用領域分類（2026-2033 年）

  • 瘤
  • 呼吸系統疾病
  • 眼科疾病
  • 其他

第9章 全球高活性藥物成分和細胞毒性藥物市場：按地區分類（2026-2033 年）

  • 北美洲
    • 美國
    • 加拿大
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
    • ASEAN
    • 其他亞太地區
  • 中東
    • GCC
    • 以色列
    • 其他中東國家
  • 非洲
    • 南非
    • 中非
    • 北非

第10章 競爭格局

  • 公司簡介
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer, Inc.
    • Lonza Group
    • Corden Pharma International
    • Evonik Industries AG
    • Flamma Group
    • Merck KGaA
    • CARBOGEN AMCIS
    • Catalent, Inc.
    • Piramal Enterprises Ltd.
    • AbbVie Inc.
    • Fareva Group
    • Cerbios-Pharma SA
    • Novasep
    • Ajinomoto Bio-Pharma
    • PCI Pharma Services
    • Sterling Pharma Solutions
    • Heraeus Holding
    • Polpharma Biologics
    • Helsinn Healthcare SA
    • Seqens
    • Cambrex Corporation

第11章

  • 參考
  • 分析方法
簡介目錄
Product Code: CMI1312

Hpapis And Cytotoxic Drugs Manufacturing Market is estimated to be valued at USD 37.78 Bn in 2026 and is expected to reach USD 64.81 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 37.78 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 8.00% 2033 Value Projection: USD 64.81 Bn

Highly potent active pharmaceutical ingredients (HPAPI) has an increasingly significant share of the pharmaceutical drug pipeline including anti-cancer treatments. Manufacturing highly potent APIs in large volumes requires extensive project experience with HPAPIs and a strong track record for audits and supply security.

Cytotoxic drugs are agents used to destroy cancer cells and tumors by inhibiting cell division. These drugs are widely used as anti-cancer agents and are used to boost the outcomes of surgery or radiotherapy, reduce metastasis, and diminish cancer symptoms.

Market Dynamics

Market players are engaged in inorganic activities, such as acquisitions, in order to expand its product portfolio, this is expected to drive the growth of the global HPAPIs and cytotoxic drugs manufacturing market, over the forecast period. For instance, in January 2019, Flamma Group, a life science company, acquired Teva's Chemical Synthesis Center, the 40,000 sq. ft. cGMP facility in Malvern (U.S.). This laboratory and manufacturing site possesses a cGMP Pilot Plant with hydrogenation capabilities as well as wet-milling, 5 standard cGMP kilo lab suites, and 1 cGMP HPAPI kilo lab suite.

Key players are focusing on receiving authorizations for their manufacturing facilities, from the regulatory authorities, and this is expected to drive the growth of the global HPAPIs and cytotoxic drugs manufacturing market, over the forecast period. For instance, in December 2019, Cerbios-Pharma SA announced the authorization by Swissmedic of its cGMP bioconjugation suite for up-to commercial scale manufacturing of Antibody Drug Conjugates (ADCs).

Moreover, in December 2019, Piramal Pharma Solutions, a division of Piramal Enterprises ltd., expanded its manufacturing facility in Riverview, Michigan, with an investment of approximately US$ 32 million to develop and manufacture potent and non-potent active pharmaceutical ingredients (API).

Key features of the study

  • This report provides an in-depth analysis of the global HPAPIs and cytotoxic drugs manufacturing market, provides market size (US$ Billion), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global HPAPIs and cytotoxic drugs manufacturing market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Lonza Group, CordenPharma International, Evonik Industries AG, Flamma Group, Merck KGaA, CARBOGEN AMCIS, Catalent, Inc., Piramal Enterprises Ltd., AbbVie Inc., Fareva Group, Cerbios-Pharma SA, Novasep, Ajinomoto Bio-Pharma, PCI Pharma Services, Sterling Pharma Solutions, Heraeus Holding, Polpharma Biologics, Helsinn Healthcare SA, Seqens, Cambrex Corporation
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global HPAPIs and cytotoxic drugs manufacturing market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global HPAPIs and cytotoxic drugs manufacturing market

Market Segmentation

  • Drug Origin Insights (Revenue, USD Bn, 2026 - 2033)
    • Chemical-based HPAPIs
    • Biologic-based HPAPIs
  • Manufacturing Location Insights (Revenue, USD Bn, 2026 - 2033)
    • In-house Manufacturing
    • Outsourcing
  • Drug Type Insights (Revenue, USD Bn, 2026 - 2033)
    • Novel HPAPIs
    • Generic HPAPIs
  • Type of Pharmacological Molecule Insights (Revenue, USD Bn, 2026 - 2033)
    • Small Molecules
    • Biologics
  • Application Insights (Revenue, USD Bn, 2026 - 2033)
    • Oncology
    • Respiratory
    • Ophthalmic Disorders
    • Others
  • Regional Insights (Revenue, USD Bn, 2026 - 2033)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer, Inc.
    • Lonza Group
    • CordenPharma International
    • Evonik Industries AG
    • Flamma Group
    • Merck KGaA
    • CARBOGEN AMCIS
    • Catalent, Inc.
    • Piramal Enterprises Ltd.
    • AbbVie Inc.
    • Fareva Group
    • Cerbios-Pharma SA
    • Novasep
    • Ajinomoto Bio-Pharma
    • PCI Pharma Services
    • Sterling Pharma Solutions
    • Heraeus Holding
    • Polpharma Biologics
    • Helsinn Healthcare SA
    • Seqens
    • Cambrex Corporation

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Origin
    • Market Snippet, By Manufacturing Location
    • Market Snippet, By Drug Type
    • Market Snippet, By Type of Pharmacological Molecule
    • Market Snippet, By Application
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Regulatory Scenario
  • PEST Analysis
  • Recent Product Launch/Approval
  • Epidemiology
  • Mergers and Acquisitions

4. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Origin, 2026-2033 (USD Bn)

  • Introduction
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Chemical-based HPAPIs
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Biologic-based HPAPIs
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends

5. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Manufacturing Location, 2026 - 2033 (USD Bn)

  • Introduction
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • In-house Manufacturing
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Outsourcing
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends

6. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Type, 2026 - 2033 (USD Bn)

  • Introduction
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Novel HPAPIs
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Generic HPAPIs
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends

7. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Type of Pharmacological Molecule, 2026 - 2033 (USD Bn)

  • Introduction
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Small Molecules
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Biologics
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends

8. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Application, 2026 - 2033 (USD Bn)

  • Introduction
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Oncology
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Respiratory
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Ophthalmic Disorders
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Others
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends

9. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Region, 2026 - 2033 (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, For Region, 2021 - 2033
  • North America
    • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
    • Y-o-Y Growth Analysis, For Country, 2021 - 2033
    • Market Size and Forecast, By Drug Origin, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Manufacturing Location, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Drug Type, 2026 - 2033(USD Bn)
    • Market Size and Forecast, By Type of Pharmacological Molecule, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Application, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Country, 2026 - 2033 (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
    • Y-o-Y Growth Analysis, For Country, 2021 - 2033
    • Market Size and Forecast, By Drug Origin, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Manufacturing Location, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Drug Type, 2026 - 2033(USD Bn)
    • Market Size and Forecast, By Type of Pharmacological Molecule, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Application, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Country, 2026 - 2033 (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
    • Y-o-Y Growth Analysis, For Country, 2021 - 2033
    • Market Size and Forecast, By Drug Origin, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Manufacturing Location, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Drug Type, 2026 - 2033(USD Bn)
    • Market Size and Forecast, By Type of Pharmacological Molecule, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Application, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Country, 2026 - 2033 (USD Bn)
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
    • Y-o-Y Growth Analysis, For Country, 2021 - 2033
    • Market Size and Forecast, By Drug Origin, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Manufacturing Location, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Drug Type, 2026 - 2033(USD Bn)
    • Market Size and Forecast, By Type of Pharmacological Molecule, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Application, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Country, 2026 - 2033 (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
    • Y-o-Y Growth Analysis, For Country, 2021 - 2033
    • Market Size and Forecast, By Drug Origin, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Manufacturing Location, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Drug Type, 2026 - 2033(USD Bn)
    • Market Size and Forecast, By Type of Pharmacological Molecule, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Application, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Country, 2026 - 2033 (USD Bn)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
    • Y-o-Y Growth Analysis, For Country, 2021 - 2033
    • Market Size and Forecast, By Drug Origin, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Manufacturing Location, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Drug Type, 2026 - 2033(USD Bn)
    • Market Size and Forecast, By Type of Pharmacological Molecule, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Application, 2026 - 2033 (USD Bn)
    • Market Size and Forecast, By Country, 2026 - 2033 (USD Bn)
      • South Africa
      • Central Africa
      • North Africa

10. Competitive Landscape

  • Company Profiles
    • Teva Pharmaceutical Industries Ltd.
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Pfizer, Inc.
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Lonza Group
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Corden Pharma International
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Evonik Industries AG
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Flamma Group
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Merck KGaA
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • CARBOGEN AMCIS
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Catalent, Inc.
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Piramal Enterprises Ltd.
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • AbbVie Inc.
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Fareva Group
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Cerbios-Pharma SA
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Novasep
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Ajinomoto Bio-Pharma
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • PCI Pharma Services
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Sterling Pharma Solutions
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Heraeus Holding
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Polpharma Biologics
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Helsinn Healthcare SA
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Seqens
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Cambrex Corporation
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
      • Analyst Views

11. Section

  • References
  • Research Methodology
  • About us and Sales Contact